TEDCO’s Life Science Investment Fund (LSIF) invests in AsclepiX Therapeutics to develop novel peptide drugs to treat ocular diseases. AsclepiX was chosen by a panel of FDA consultants, investors, and C-level biotechnology and life science executives. TEDCO’s Life Science Investment Fund is specifically designed for companies that are beyond the technology validation stage and further along in product development.
AsclepiX Therapeutics is pleased to welcome Wendy Perrow, MBA, as Chief Executive Officer of AsclepiX Therapeutics. Ms. Perrow previously served as CEO of Alba Therapeutics. The company conducted seven clinical trials in patients with Celiac Disease, completed the largest Phase IIb clinical trial in patients with celiac disease and validated the 1st Celiac Disease Patient Reported Outcome (CeD PRO) with the lead compound Larazotide Acetate. Prior to joining AsclepiX, Ms. Perrow held senior executive positions with private and public pharmaceutical companies. From 2004 to 2007, she was Vice President of Marketing for Sigma-Tau Pharmaceuticals, Inc., a company focused on creating novel therapies for the unmet needs of patients with Rare and Orphan Diseases. From 1989 to 2003, Ms. Perrow was at Merck and Co., Inc. in Global markets including Europe, Asia, and Latin America and U.S. At Merck, she held positions in marketing, marketing promotion, international business research analysis, training, and sales. A skilled marketer and business leader, she has led U.S. and Global launches/initiatives for Zocor®, Vasotec®, Varivax®, Cozaar® and Hyzaar®. Ms. Perrow received her MBA in International finance and marketing from The Fuqua School of Business at Duke University and received her bachelor’s degree from Eastern Illinois University. Dr. Jordan Green, the founding CEO of AsclepiX Therapeutics, will continue to serve AsclepiX as its Chief Technology Officer.
AsclepiX Therapeutics has been invited to attend the 2016 Angel Capital Association Summit and present at the Innovation Showcase on May 10, 2016, with sponsorship by the Maryland Innovation Initiative.
Dr. Green, CEO of AsclepiX Therapeutics, was named a recipient of the Outstanding New Investigator Award by the American Society of Gene & Cell Therapy (ASGCT) and will present an invited talk of his work at ASCGT’s 19th Annual Meeting in Washington, DC in May
Dr. Green, CEO of AsclepiX Therapeutics, is named as a recipient of a Presidential Early Career Award for Scientists and Engineers, the “highest honor bestowed by the United States Government on science and engineering professionals in the early stages of their independent research careers.” “These early-career scientists are leading the way in our efforts to confront and understand challenges from climate change to our health and wellness,” President Obama said. “We congratulate these accomplished individuals and encourage them to continue to serve as an example of the incredible promise and ingenuity of the American people.”
Dr. Green, CEO of AsclepiX Therapeutics, is an invited participant at the 8th Annual Conference of the Arnold and Mabel Beckman Initiative for Macular Research (BIMR). BIMR brings together outstanding researchers to discuss ideas related to issues in Age-related Macular Degeneration research at the Beckman Center of the National Academies of Sciences and Engineering in Irvine, CA.
Dr. Green, CEO of AsclepiX Therapeutics, is selected by Baltimore Business Journal as one of the “40 Under 40.”
AsclepiX Therapeutics receives a $278,000 grant from the National Eye Institute to develop an innovative drug to treat macular edema.
Dr. Green, CEO of AsclepiX Therapeutics, is selected to receive the American Institute of Chemical Engineers Nanoscale Science & Engineering Forum Young Investigator Award. The award is for “outstanding interdisciplinary research in nanoscience and nanotechnology.”
AsclepiX Therapeutics is highlighted in the Johns Hopkins University Whiting School of Engineering Summer 2015 Magazine for their initiatives and technology tackling blindness.
BIO 2015 is underway. Come visit AsclepiX Therapeutics at Booth #301.
AsclepiX Therapeutics is thrilled to participate in the 2015 BIO International Convention. The AsclepiX booth is located in the BioMaryland Pavilion and is Booth #301. Dr. Jordan Green will also be speaking as an invited panelist at session #1583, “I-Corps™ at NIH: Success stories from the Lean Launchpad Entrepreneurial Bootcamp with NIH SBIR Companies.”
AsclepiX Therapeutics is highlighted in the Wilmer Eye Institute’s SightLine Publication for Spring 2015. The Johns Hopkins University and the Wilmer Eye Institute are fostering innovation and entrepreneurship through initiatives such as FastForward, the incubator that AsclepiX moved into last year.
AsclepiX CSO, Dr. Aleksander Popel, is profiled by Johns Hopkins University on his work at halting cancer’s spread and on starting AsclepiX Therapeutics. Dr. Popel and his lab have developed peptides that prevent the growth of angiogenic blood vessels and lymphatic vessels and that have showed efficacy in multiple cancer animal models.
AsclepiX Therapeutics is pleased to be one of the invited start-up company presenters at the 2015 Annual Joint Meeting Johns Hopkins Alliance for Science & Technology Development and the University of Maryland, Baltimore Commercial Advisory Board. AsclepiX will give an update on its progress in ocular therapeutics at the meeting.
The commercialization experiences and customer discovery of NIH-funded biomedical companies, including AsclepiX Therapeutics, are highlighted in a new article in Nature, “Biotech Boot Camp,“ published today. The article discusses the new pilot NIH I-Corps program and how it adds value by focusing the commercialization pathway of biotechnology startups.
AsclepiX Therapeutics is excited to be an invited presenter at the Stanford-Coulter Innovation Forum. AsclepiX Therapeutics was one of the companies selected nationally from among all the projects that have received funding from the Wallace H. Coulter Foundation. A goal of the Coulter Foundation and the Stanford-Coulter Innovation Forum is to accelerate promising translational innovations in biomedical engineering.
AsclepiX Therapeutics CEO, Dr. Jordan Green was selected as one of the 2015 Nifty Fifty. This is a group of the most dynamic scientists and engineers in the United States. They were selected for their unique ability to inspire the next generation of students to pursue careers in the STEM fields. They were chosen from among thousands of candidates nominated by over 500 leading professional science and engineering societies, universities, research institutions, government agencies, STEM education outreach organizations and leading high tech and life science companies.
AsclepiX Therapeutics is excited to participate in the inaugural cohort of the NIH Innovation Corps (I-Corps™) Team Training Pilot Program. This NIH program “seeks to accelerate the development and commercialization of new products and services arising from projects supported by currently funded NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) awards.”
AsclepiX Therapeutics CEO, Jordan Green, is named one of the “Brilliant Ten” of 2014 by Popular Science. The selection process takes Popular Science six months to “identify the most inspired young scientists and engineers—researchers whose ideas will transform the future.”
Breast Cancer Cells Promote Metastasis Through Lymphatic Cells
‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread. HIV drug plus blood vessel growth-blockers could halt metastasis
Tumor Cells May Encourage Lymphatic Cells to Spread Breast Cancer – And a New Treatment Could Stop It.
Genetic Engineering & Biotechnology News. Lymphatic Cells Shill for Breast Cancer.
New research shows the critical role of lymphatic vessels in cancer and metastasis. AsclepiX Therapeutics has developed novel compounds that inhibit the growth of lymphatic vessels.
AsclepiX Therapeutics receives $233,000 from National Cancer Institute to develop innovative nanobiotechnology to treat cancer.
AsclepiX Therapeutics is highlighted again by the Baltimore Business Journal, who visited AsclepiX Therapeutics to learn more about AsclepiX’s work on treating ocular diseases such as macular edema.
AsclepiX Therapeutics is highlighted by the Baltimore Business Journal as one of eight startup companies to receive a $100,000 Maryland Innovation Initiative Award in 2014. This award funds AsclepiX Therapeutic’s work on treating macular edema utilizing technology licensed from Johns Hopkins University.
AsclepiX Therapeutics welcomes Dr. Peter Campochiaro and Dr. Henry Brem, world-renowned scientists and clinicians, to the Scientific Advisory Board.
AsclepiX Therapeutics receives $260,000 from National Eye Institute to develop innovative biotechnology to treat neovascular age-related macular degeneration.
AsclepiX Therapeutics is featured on the Johns Hopkins University FastForward website as the latest startup to join the incubator.
AsclepiX Therapeutics receives $200,000 from BioMaryland to accelerate the commercialization of their technology on developing a long-lasting drug which would reduce the number of eye injections for macular degeneration and improve patient vision.
Collaboration with the Johns Hopkins Carey Business School and the Discovery to Market technology transfer course on developing treatments for AMD highlighted in The Washington Post
BME researchers testing promising drug therapy delivery method for improved treatment of central vision loss
Johns Hopkins’ biomedical engineers to create therapeutic eye injections
Time-release coating allows drug for macular degeneration to last longer
Time-release delivery of vision-loss drug demands fewer injections
Therapeutic eye injections may be needed less often
The Coulter Foundation funds co-founders Dr. Green and Dr. Popel at the Johns Hopkins University for a second year ($200,000 total) to continue the translation of their AMD therapy.
Maryland Innovation Initiative funds co-founders Dr. Green and Dr. Popel at the Johns Hopkins University $100,000 to develop a long-acting therapeutic for age-related macular degeneration.